Equities research analysts predict that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will post earnings per share of ($0.60) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Portola Pharmaceuticals’ earnings, with estimates ranging from ($0.79) to ($0.44). Portola Pharmaceuticals posted earnings of ($1.04) per share in the same quarter last year, which would indicate a positive year over year growth rate of 42.3%. The firm is expected to report its next quarterly earnings report on Friday, March 6th.

On average, analysts expect that Portola Pharmaceuticals will report full year earnings of ($3.05) per share for the current financial year, with EPS estimates ranging from ($3.50) to ($2.59). For the next year, analysts anticipate that the business will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.77) to ($1.43). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Portola Pharmaceuticals.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.14. Portola Pharmaceuticals had a negative net margin of 275.13% and a negative return on equity of 282.04%. The business had revenue of $36.80 million during the quarter, compared to analysts’ expectations of $34.64 million. During the same period in the previous year, the company earned ($1.08) earnings per share. Portola Pharmaceuticals’s revenue for the quarter was up 159.2% on a year-over-year basis.

A number of brokerages recently issued reports on PTLA. Morgan Stanley began coverage on shares of Portola Pharmaceuticals in a research report on Thursday, September 5th. They set a “hold” rating and a $37.00 target price on the stock. Goldman Sachs Group began coverage on shares of Portola Pharmaceuticals in a research report on Friday, November 8th. They set a “neutral” rating and a $35.00 target price on the stock. Credit Suisse Group reaffirmed a “neutral” rating and set a $35.00 target price on shares of Portola Pharmaceuticals in a research report on Monday, August 5th. ValuEngine lowered shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, October 21st. Finally, Zacks Investment Research raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a report on Wednesday, October 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $38.75.

In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $30.00, for a total value of $150,000.00. Following the sale, the director now owns 18,194 shares of the company’s stock, valued at approximately $545,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.50% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Next Capital Management LLC bought a new stake in Portola Pharmaceuticals in the 2nd quarter valued at $27,000. Point72 Hong Kong Ltd bought a new stake in shares of Portola Pharmaceuticals in the 2nd quarter worth about $31,000. Tower Research Capital LLC TRC bought a new stake in shares of Portola Pharmaceuticals in the 3rd quarter worth about $42,000. Cornerstone Advisors Inc. grew its holdings in shares of Portola Pharmaceuticals by 34.6% in the 3rd quarter. Cornerstone Advisors Inc. now owns 1,801 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 463 shares during the last quarter. Finally, Valley National Advisers Inc. grew its holdings in shares of Portola Pharmaceuticals by 32.0% in the 2nd quarter. Valley National Advisers Inc. now owns 4,046 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 981 shares during the last quarter. 95.39% of the stock is currently owned by hedge funds and other institutional investors.

PTLA stock traded up $1.11 on Friday, reaching $29.16. 66,163 shares of the company were exchanged, compared to its average volume of 752,980. Portola Pharmaceuticals has a 12 month low of $14.81 and a 12 month high of $37.95. The stock’s fifty day moving average price is $27.94 and its 200 day moving average price is $28.37. The firm has a market capitalization of $2.12 billion, a PE ratio of -5.82 and a beta of 2.08. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.88 and a quick ratio of 5.85.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Featured Story: Fibonacci Channel

Get a free copy of the Zacks research report on Portola Pharmaceuticals (PTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.